Abstract
We have utilized deceased donor livers to maintain low mortality on the wait list, to provide a significantly high transplant rate, and to achieve excellent graft and patient outcomes at 3 months, one year, and 3 years, surpassing the national and expected averages. We have also shown that reLT remains a durable option for patients with recurrent disease including recurrent HCV, that DCD livers continue to be a viable source of donor grafts, and that LT in patients with high BMI produces acceptable outcomes.
Original language | English (US) |
---|---|
Pages (from-to) | 127-135 |
Number of pages | 9 |
Journal | Clinical transplants |
State | Published - 2008 |
ASJC Scopus subject areas
- General Medicine